Breaking News

U.S. May Home Prices Rise 0.4% From Previous Month: FHFA
Tweet TWEET

Bristol-Myers Approved to Market Erbitux for Wider Cancer Use

Bristol-Myers Squibb Co. (BMY) won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.

The Food and Drug Administration cleared the medicine for use with chemotherapy to treat patients with head and neck cancer that has spread, the agency said today in a statement. Bristol-Myers licenses the drug from Eli Lilly & Co. (LLY)

Erbitux, made by Indianapolis-based Lilly’s ImClone unit, already is approved in the U.S. to treat colon cancer and head and neck tumors that haven’t spread. Bristol-Myers, based in New York, generated $662 million in 2010 sales from the drug, while Lilly’s manufacturing revenue was $71.9 million. Lilly acquired ImClone in 2008.

“Erbitux’s ability to extend the lives of patients with head and neck cancers is an important tool for oncologists who often rely on a multitreatment approach for patients,” Richard Pazdur, director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research, said in the statement.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.